Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 18,300 shares, a decline of 10.7% from the December 31st total of 20,500 shares. Approximately 0.3% of the company’s shares are sold short. […]
Indaptus Therapeutics, Inc. (NASDAQ:INDP – Free Report) – Analysts at HC Wainwright increased their FY2023 earnings estimates for shares of Indaptus Therapeutics in a research report issued on Tuesday, November 7th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.90) per share for the year, up from their previous estimate of […]
HC Wainwright restated their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock. Indaptus Therapeutics Stock Down 18.6 % Indaptus Therapeutics stock opened at $2.71 on Wednesday. The firm has a […]
Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 46,700 shares, a growth of 115.2% from the July 31st total of 21,700 shares. Approximately 0.8% of the shares of the stock are […]
Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) major shareholder Glen R. Anderson bought 44,354 shares of the stock in a transaction on Thursday, August 10th. The shares were acquired at an average cost of $1.94 per share, for a total transaction of $86,046.76. Following the purchase, the insider now owns 1,131,402 shares in the […]